BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Arcosa, Inc. (NYSE – ACA), Fathom Holdings Inc. (Nasdaq – FTHM), Nuvalent, Inc. (Nasdaq – NUVL), Dana Incorporated (NYSE – DAN)

Law firm Brodsky & Smith announced investigations into four major merger transactions, examining whether company boards breached fiduciary duties by failing to conduct fair processes and provide fair value to shareholders. The investigations involve Arcosa (CRH acquisition for $150/share), Fathom Holdings (Bed Bath & Beyond acquisition), Nuvalent (GSK acquisition for $124/share), and Dana Incorporated (Eaton Corporation acquisition).

06/22/2026, 1:43 PM • GlobeNewswire

The M&A Class Action Firm Encourages $hareholders to Contact Monteverde Concerning The Merger—PFLC, NUVL, CCRN, and BGMS

Monteverde & Associates PC is investigating four merger and acquisition transactions on behalf of shareholders. Pacific Financial Corporation is merging with Banner Corporation (0.2633 shares per share), Nuvalent Inc. is being acquired by GSK plc ($124.00 per share), Cross Country Healthcare is being sold to KL Criss Cross Intermediate LLC ($13.25 per share), and Bio Green Med Solution is merging with Future NRG Sdn. Bhd. Shareholders are encouraged to contact the firm regarding potential concerns with these transactions.

06/18/2026, 6:10 PM • GlobeNewswire

Halper Sadeh LLC is Investigating Whether LPRO, NUVL, OGN, SUNE are Obtaining Fair Deals for their Shareholders

Investor rights law firm Halper Sadeh LLC is investigating four companies for potential securities law violations and breaches of fiduciary duties related to their proposed acquisitions. The firm is examining whether shareholders are receiving fair consideration and whether insider benefits may be limiting superior competing offers.

06/16/2026, 9:14 PM • GlobeNewswire

Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 Billion

GSK announced a $10.6 billion all-cash acquisition of Nuvalent at $124 per share, representing a 40% premium. The deal reflects Big Pharma's aggressive capital deployment to address an impending patent cliff, as GSK faces revenue loss from dolutegravir's expiring exclusivity. Nuvalent brings two late-stage kinase inhibitors targeting non-small cell lung cancer with FDA Breakthrough Therapy designations, triggering a short squeeze and signaling potential industry consolidation in oncology.

06/11/2026, 1:18 PM • Investing

Halper Sadeh LLC is Investigating Whether NUVL, SUNE, OGN, TMHC are Obtaining Fair Deals for their Shareholders

Investor rights law firm Halper Sadeh LLC is investigating four major corporate transactions for potential securities law violations and breaches of fiduciary duties. The investigations cover Nuvalent's $124/share sale to GSK, SUNation Energy's merger with Suniva, Organon's $14/share sale to Sun Pharmaceutical, and Taylor Morrison's $72.50/share sale to Berkshire Hathaway. The firm is seeking increased consideration and additional disclosures on behalf of shareholders.

06/09/2026, 8:04 PM • GlobeNewswire

Nasdaq 100 Tumbles Over 3%, Marvell Crashes 12%: Stock Market Today

U.S. stocks declined sharply on Tuesday as investors rotated out of high-flying chip and AI stocks. The Nasdaq 100 fell 3.3%, the S&P 500 dropped 1.6%, and the Russell 2000 fell 1.3%. Oil prices collapsed 6% following a halt in Israel-Iran strikes. Markets are now pricing in a potential Fed rate hike by October rather than cuts, pressuring richly valued tech stocks. Semiconductor and optical companies led losses, while defensive and financial sectors provided some cushion.

06/09/2026, 1:26 PM • Benzinga

GSK Makes Its Biggest Bet In More Than A Decade, Paying $10.6 Billion For Cancer Drug Developer Nuvalent

GSK agreed to acquire Nuvalent for $10.6 billion in cash, marking its largest acquisition in over a decade. The deal provides GSK with three lung cancer assets including lead drug candidates zidesamtinib and neladalkib for non-small cell lung cancer treatment. The acquisition is expected to contribute to revenue growth and be accretive to sales and core operating profit beginning in 2027.

06/09/2026, 6:52 AM • Benzinga

Non-Small Cell Lung Cancer Clinical Trial Race Intensifies as 100+ Companies Competing in Therapeutic Segment Worldwide | DelveInsight

Over 100 pharmaceutical companies are competing to develop 120+ pipeline drugs for non-small cell lung cancer (NSCLC), with approximately 30+ drugs in late-stage development. The competitive landscape is driven by precision oncology advances, including next-generation targeted agents and immunotherapy combinations. Recent FDA approvals and designations highlight innovation in treating EGFR-mutated, ALK-positive, and other biomarker-selected NSCLC populations.

04/16/2026, 1:00 PM • GlobeNewswire

This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally

Vestal Point Capital sold 1.054 million shares of Nuvalent (NUVL) for approximately $103.93 million in Q4, reducing its position to less than 1% of assets under management. Despite the sale, Nuvalent shares have rallied nearly 30% over the past year and the company is well-positioned financially with $1.4 billion in cash, awaiting potential FDA decisions on its cancer drug candidates later in 2026.

03/16/2026, 8:00 PM • The Motley Fool

Biotech Fund Dumps $84 Million of Nuvalent With Stock Up 29%

Commodore Capital reduced its Nuvalent stake by 850,000 shares (worth $83.81 million) in Q4 2025, cutting the position from 9.26% to 3.68% of assets. Despite the sale, Nuvalent shares are up 29% over the past year and the company maintains strong cash runway into 2029 with upcoming FDA catalysts including a PDUFA date for zidesamtinib in September.

02/23/2026, 10:01 AM • The Motley Fool

What's Going On With Royalty Pharma Stock Wednesday?

Royalty Pharma acquired the final portion of PTC Therapeutics' royalty on Roche's Evrysdi for $240 million upfront plus up to $60 million in milestones, giving it 100% ownership of the 8-16% tiered royalty. Evrysdi generated $1.9 billion in 2024 sales with projected growth to $2.9 billion by 2030. RPRX stock is up 53% year-to-date but down slightly on Wednesday. The company also recently acquired royalty interests in Nuvalent's cancer drugs.

12/31/2025, 10:47 AM • Benzinga

Nuvalent (NUVL) Q2 R&D Up 65%

Nuvalent, a clinical-stage biotechnology company, reported a Q2 2025 net loss of $99.7 million while advancing its oncology pipeline, focusing on kinase mutation therapies for lung cancer. The company continues developing zidesamtinib and neladalkib, with potential drug launches anticipated in 2026.

08/07/2025, 8:18 AM • The Motley Fool